Management of Hematuria in Renal Transplant Recipients

Initial Assessment

• Evaluate the timing post-transplant: management differs between early (<1 month) and late (>1 month) post-transplant periods 1, 2
• Assess for associated symptoms: fever, graft tenderness, decreased urine output, or changes in graft function 3
• Review medication history, particularly anticoagulants and immunosuppressive regimens 3
• Quantify hematuria and check for concurrent proteinuria 4, 5

Diagnostic Workup

Laboratory Evaluation

• Urine culture to rule out infection, with specific consideration for atypical pathogens in immunosuppressed patients 3
• Serum creatinine and estimated GFR to assess graft function 5
• Evaluate for markers of recurrent glomerular disease if relevant to the patient's original kidney disease 6, 4

Definitive Diagnosis

• Kidney allograft biopsy is recommended when there is persistent, unexplained hematuria, especially if accompanied by graft dysfunction or significant proteinuria 6, 4

Management Based on Etiology

Infection-Related Hematuria

• For urinary tract infections with hematuria, treat with appropriate antibiotics based on culture and sensitivity 3
• For severe or life-threatening UTI with fever, temporarily reduce immunosuppression until infection resolves 3
• The IDSA recommends against screening for or treating asymptomatic bacteriuria in renal transplant recipients who are more than 1 month post-transplant 7, 3

Recurrent Glomerular Disease

• For patients with primary FSGS presenting with hematuria and proteinuria, consider plasma exchange 4
• For recurrent ANCA-associated vasculitis or anti-GBM disease with hematuria, high-dose corticosteroids and cyclophosphamide are suggested 4, 8
• For recurrent glomerulonephritis with proteinuria, consider using an ACE inhibitor or ARB 4

Screening and Prevention

• For patients with history of recurrent glomerular diseases:
  • Screen for microhematuria at least once in the first month to establish baseline 4
  • Continue screening every 3 months during the first year 4
  • Annual screening thereafter 4

Common Pitfalls to Avoid

• Failure to consider recurrent primary kidney disease as a cause of hematuria 4
• Excessive reduction in immunosuppression during infection management may trigger rejection 3
• Delaying biopsy when there is unexplained hematuria with graft dysfunction or significant proteinuria 6, 4

Post‑Kidney Transplant Hematuria – Evidence‑Based Evaluation and Management

1. Assessment and Treatment of Graft‑Intolerance Syndrome

• First‑line therapy: Administer high‑dose pulse corticosteroids to patients with a failing allograft who present with hematuria, fever, and graft tenderness. This approach is recommended by the American Society of Transplantation based on data from two 2021 studies. [9][10]
• Infection prevalence: Approximately 38 % of fevers occurring in failed allografts are due to infectious causes (most commonly dialysis‑catheter‑related infections), underscoring the need to rule out infection before assuming rejection. Evidence from the same 2021 transplant cohort studies. [9][10]
• Surgical option: Consider transplant nephrectomy when hematuria is accompanied by persistent hemorrhage, unrelenting graft pain, or failure of medical therapy. Recommendation derived from the 2021 American Journal of Transplantation reports. [9][10]

2. Imaging Strategy for Hematuria in Kidney‑Transplant Recipients

• Preferred initial modality: Perform a non‑contrast CT scan of the abdomen and pelvis to evaluate for hemorrhage, urinary obstruction, nephrolithiasis, peritransplant fluid collections, and masses while avoiding contrast‑induced nephrotoxicity in a potentially compromised graft. Guidance from the American College of Radiology (2025). 11
• Alternative imaging: Use renal ultrasound with Doppler assessment as an alternative when CT is unavailable or contraindicated; it can detect hydronephrosis, focal masses, and vascular complications. Based on the same 2025 radiology guideline. 11
• Contrast‑enhanced CT: Reserve contrast‑enhanced CT for cases where detailed characterization of a suspected mass or vascular abnormality is required, and only if the graft’s functional status permits safe administration of iodinated contrast. Recommendation from the 2025 American College of Radiology guidance. 11

All bullet points are derived from peer‑reviewed sources and include the citation identifiers as requested.